Diploma PLC lifts FY26 guidance: stronger organic growth and fatter margins
Diploma PLC has upgraded its FY26 guidance on the back of very strong trading in the first half and confidence heading into the second. The headline moves are meaningful: organic revenue growth nudged up to 9% (from 6%), operating margin to around 25% (from around 22.5%), and management flag a circa 13% uplift versus consensus operating profit.
For a FTSE 100 “value‑add solutions” group that prides itself on sustainable quality compounding, this is exactly the sort of update long-term holders like to see.
Key upgrades at a glance
| Metric | New FY26 guidance | Prior guidance | Notes |
|---|---|---|---|
| Organic revenue growth | 9% (H1 weighted) | 6% | Strong first half; growth normalises in H2 against tough comparators |
| Net acquisition growth | 3% | 3% | Could increase if further acquisitions complete; not baked into guidance |
| Operating margin | c.25% | c.22.5% | Approx. 2.5 percentage points of expansion, driven by mix and execution |
| Upgrade vs consensus operating profit | c.13% | – | Consensus adjusted operating profit was £377m as at 17 March 2026 |
| Earnings growth | Over 20% | – | Management expect another year of “sustainable quality compounding” |
To put that 13% upgrade in context, c.13% of £377m implies roughly a £49m step-up versus the market’s prior view (approximate, based on the company’s consensus reference).
What’s driving the beat: segment-by-segment
Controls: Peerless out in front, Windy City Wire humming
The Controls division is the star turn. Peerless continues to benefit from favourable aerospace demand and supply dynamics, and management call out an “outstanding” organic growth performance in H1. Expect H2 to revert to more typical growth rates as comparisons stiffen, but the trajectory remains strong.
Elsewhere in Controls, IS Group and Clarendon are executing well in structurally growing end markets such as energy, defence and aerospace. Windy City Wire is also performing very well, with growth supported by datacentres and digital antenna systems. Management still expect good growth in H2 despite strong comparators.
Seals: North America solid, International a drag (especially the UK)
North American Seals shows “good progress”, underpinned by core infrastructure demand and new opportunities in nuclear power generation. That’s helpful given the long project cycles in those verticals.
International Seals remains challenging, particularly in the UK, and will hold back overall Seals growth in H1, broadly consistent with FY25 growth rates. Translation: the division is doing fine in North America, but softness elsewhere is muting the headline.
Life Sciences: gaining share in a tough healthcare market
Despite a difficult healthcare backdrop, Diploma says it is winning share across medtech and IVD (in vitro diagnostics). Importantly, organic growth excluding Peerless is strong and “well ahead” of the company’s financial model. That suggests the portfolio is carrying its weight, not just riding on the aerospace upswing.
Margin expansion: mix and execution doing the heavy lifting
Group operating margin guidance rises to around 25%, up from around 22.5%. That is a sizeable improvement of roughly 250 basis points (a basis point is one-hundredth of a percentage point). Management attribute this to an accretive contribution from Peerless and steady accretion across the rest of the group.
The message: higher-quality revenue mix and disciplined pricing/operations are dropping through to profit. Combined with 9% organic growth, that is a powerful earnings algorithm.
Acquisition machine still turning, but not in the numbers (yet)
Diploma completed eight acquisitions across the past two quarters for around £130m, with expected annualised operating profit of around £20m. The short-term pipeline is described as healthy, and management are optimistic about further deals in the months ahead.
Crucially, potential acquisitions are not reflected in the new guidance. If the M&A pace continues, the 3% net acquisition growth line has room to rise, offering upside optionality.
Why this matters for investors
- Upgraded growth and fatter margins in one go is rare. It signals strong demand and tight execution across a diversified portfolio.
- Controls – led by Peerless and Windy City Wire – is doing a lot of the heavy lifting. That mix shift supports margins without starving other divisions of investment.
- Seals International is a known soft spot, especially in the UK, but North America’s momentum and nuclear exposure help offset the drag.
- Life Sciences is quietly outperforming internal plans despite a tough market. Share gains in medtech and IVD are encouraging for durability.
- Diploma’s long-term record remains intact: the company reminds us it has grown adjusted EPS by around 18% per year on average over seven years, through a blend of organic growth and acquisitions.
Balanced view: positives and watchouts
What looks positive
- 9% organic growth, H1 weighted, suggests near-term momentum is strong.
- c.25% operating margin points to sustained mix and pricing power.
- c.13% upgrade to consensus operating profit indicates expectations were too low.
- M&A provides upside that is not in guidance, with recent deals already contributing.
What to keep an eye on
- Comparators get tougher in H2 for Peerless and Windy City Wire, so growth is expected to normalise.
- International Seals, particularly the UK, remains a headwind to divisional growth.
- Healthcare markets are still “tough” even as Life Sciences gains share – execution has to stay sharp.
What’s not disclosed in this update
No new detail on cash flow, net debt, order book, or dividend policy – all not disclosed here. We should get a fuller financial picture at the half year results on 19 May 2026.
Timeline and next catalysts
- Conference call for analysts and investors at 8:00am (UK time) today.
- Half year results: 19 May 2026.
- Any additional acquisitions could lift the 3% net acquisition growth line – guidance does not include potential deals.
Bottom line: guidance moved up, quality intact
Diploma is guiding to faster organic growth and significantly higher margins, with momentum broad-based across Controls and Life Sciences. Seals International is a blemish, but it does not overshadow the group narrative.
With earnings growth guided at over 20% and returns on capital described as strong, this reads like another year of “sustainable quality compounding”. If management keep executing – and if M&A adds as expected – the upgraded FY26 outlook may not be the last positive revision we see this year.
